Mitochondrial metabolism is a key determinant of chemotherapy sensitivity in Colorectal Cancer
Moss, D. Y.; Brown, C.; Shaw, A.; McCann, C.; Lewis, N.; Phillips, A.; Gallagher, S.; McDaid, W. J.; Roe, A.; Coughlan, A. Y.; Cavanagh, B.; Ormsby, C.; Falcone, F.; McCole, R.; Monteith, S.; Rogan, E.; Downs, M.; Malla, S. B.; Emerson, A. J.; Mohammed-Smith, L.; Sharkey, S.; Gallagher, P. F.; Banerjee, A.; Pandor, S.; Greer, B.; Elliott, C.; Ryan, A.; Dunne, P. D.; Coyle, V.; Mills, I. G.; McDade, S. S.; Sansom, O.; Ni Chonghaile, T.; Longley, D. B.; LaBonte, M. J.; Kerr, E. M.
Show abstract
Therapy resistance is attributed to over 80% of cancer deaths per year emphasizing the urgent need to overcome this challenge for improved patient outcomes. Despite its widespread use in colorectal cancer (CRC) treatment, resistance to 5-fluorouracil (5FU) remains poorly understood. Here, we investigate the transcriptional responses of CRC cells to 5FU treatment, revealing significant metabolic reprogramming towards heightened mitochondrial activity. Utilizing CRC models, we demonstrate sustained enhancement of mitochondrial biogenesis and function following 5FU treatment, leading to resistance in both in vitro and in vivo settings. Furthermore, we show that targeting mitochondrial metabolism, specifically by inhibiting Complex I (CI), sensitizes CRC cells to 5FU, resulting in delayed tumour growth and prolonged survival in preclinical models. Additionally, our analysis of patient data suggests that oxidative metabolism signatures may predict responses to 5FU-based chemotherapy. These findings shed light on mechanisms underlying 5FU resistance and propose a rational strategy for combination therapy in CRC, emphasizing the potential clinical benefit of targeting mitochondrial metabolism to overcome resistance and enhance patient outcomes.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncology 96%
- GLUT1 inhibition blocks growth of RB1-positive Triple Negative Breast Cancer 96%
- Combining RASG12C(ON) inhibitor with SHP2 inhibition sensitises immune excluded lung tumours to immune checkpoint blockade: a strategy for turning cold tumours hot 95%
Similar papers in this journal
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 96%
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 96%
- Multiplexed mosaic tumor models reveal natural phenotypic variations in drug response within and between populations 94%
Similar papers in this journal
- Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models 95%
- Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments 94%
- Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors 94%
Similar papers in this journal
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 95%
- eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules 95%
- Identifying a gene signature of metastatic potential by linking pre-metastatic state to ultimate metastatic fate 94%
Similar papers in this journal
- Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal Adenocarcinoma 95%
- Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting 94%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.